Genscript Biotech (HK:1548) has released an update.
Genscript Biotech’s subsidiary, Legend Biotech, reported that CARVYKTI® generated approximately $286 million in net trade sales for the quarter ending September 30, 2024. This figure highlights the significant commercial progress of CARVYKTI® under a collaboration with Janssen Biotech. Investors may find this development noteworthy as it underscores the potential financial impact on the company’s stock performance.
For further insights into HK:1548 stock, check out TipRanks’ Stock Analysis page.
